Cargando…

The early effect of dapagliflozin on strain and tissue Doppler parameters of diastolic function in diabetic patients with heart failure with reduced ejection fraction

INTRODUCTION: Heart failure (HF) with reduced ejection fraction (HFrEF) remains a challenging problem due to its high mortality rate. The PARADIGM HF trial and a new class of drugs – angiotensin receptor–neprilysin inhibitors (ARNIs) – managed to change the current perception of HF treatment by redu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maragkoudakis, Spyridon, Marketou, Maria, Katsi, Vasiliki, Patrianakos, Alexandros, Tsigkriki, Labrini, Mamaloukaki, Maria, Tsioufis, Kostas, Kochiadakis, George, Parthenakis, Fragkiskos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2021
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8525245/ https://www.ncbi.nlm.nih.gov/pubmed/34703947 http://dx.doi.org/10.5114/amsad.2021.109685

Ejemplares similares

The cardiovascular burden of light smoking
por: Katsi, Vasiliki, et al.
Publicado: (2021)

Peripheral Blood MicroRNAs as Potential Biomarkers of Myocardial Damage in Acute Viral Myocarditis
por: Marketou, Maria, et al.
Publicado: (2021)

Anomalous left atrial chord as a rare cause of mitral regurgitation
por: Patrianakos, Alexandros Petros, et al.
Publicado: (2020)

Cardiac Paraganglioma: Multimodality Imaging of a Rare Tumor
por: Patrianakos, Alexandros P., et al.
Publicado: (2021)

Detection of abnormal left ventricular geometry in patients without cardiovascular disease through machine learning: An ECG‐based approach
por: Angelaki, Eleni, et al.
Publicado: (2021)

The role of Ivabradine in Diastolic Heart Failure with preserved Ejection Fraction. A Doppler-Echocardiographic study
por: Cacciapuoti, Federico, et al.
Publicado: (2017)

Pathological Left Ventricular Hypertrophy and Stem Cells: Current Evidence and New Perspectives
por: Marketou, Maria E., et al.
Publicado: (2016)

Atherosclerosis, Diabetes Mellitus, and Cancer: Common Epidemiology, Shared Mechanisms, and Future Management
por: Katsi, Vasiliki, et al.
Publicado: (2023)

Asymptomatic papillary fibroelastoma of the Aortic valve in a young woman - a case report
por: Parthenakis, Fragiskos, et al.
Publicado: (2009)

Detection of left ventricular hypertrophy on the ECG through machine learning with a focus on obesity
por: Angelaki, E, et al.
Publicado: (2022)

Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver?
por: Williams, David M., et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction
por: Blair, Hannah A.
Publicado: (2021)

Dapagliflozin and Empagliflozin in Heart Failure with Reduced Ejection Fraction: A Retrospective Study
por: Hao, Zhengyang, et al.
Publicado: (2022)

Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Docherty, Kieran F., et al.
Publicado: (2022)

Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index
por: Adamson, Carly, et al.
Publicado: (2021)

Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial
por: Vardeny, Orly, et al.
Publicado: (2022)

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
por: Jackson, Alice M., et al.
Publicado: (2020)

Two-dimensional global and segmental longitudinal strain: are the results from software in different high-end ultrasound systems comparable?
por: Patrianakos, Alexandros P, et al.
Publicado: (2015)

Diastolic Ventricular Interaction in Heart Failure With Preserved Ejection Fraction
por: Parasuraman, Sathish K., et al.
Publicado: (2019)

Diastolic Dysfunction With Preserved Ejection Fraction After the Fontan Procedure
por: Chowdhury, Shahryar M., et al.
Publicado: (2022)

Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
por: Solomon, Scott D., et al.
Publicado: (2021)

Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
por: Chatur, Safia, et al.
Publicado: (2023)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with reduced ejection fraction in the Philippines
por: Mendoza, Victor L., et al.
Publicado: (2021)

Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA‐HF
por: Butt, Jawad H., et al.
Publicado: (2021)

Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF
por: Jhund, Pardeep S., et al.
Publicado: (2021)

Chrononutrition in Cardiometabolic Health
por: Katsi, Vasiliki, et al.
Publicado: (2022)

Pulmonary Hypertension in Elderly Patients with Diastolic Dysfunction and Preserved Ejection Fraction
por: Afshar, Majid, et al.
Publicado: (2012)

Impact of Updated Guidelines on Diastolic Dysfunction in Patients with Preserved Ejection Fraction
por: Yoon, Hyun Ju
Publicado: (2021)

Diastolic dysfunction in individuals with and without heart failure with preserved ejection fraction
por: Wenzel, Jan-Per, et al.
Publicado: (2021)

NADPH Oxidases in Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction
por: Teuber, James P., et al.
Publicado: (2022)

Dapagliflozin Impact on the Exercise Capacity of Non-Diabetic Heart Failure with Reduced Ejection Fraction Patients
por: Reis, João, et al.
Publicado: (2022)

Cost‐utility analysis of add‐on dapagliflozin in heart failure with preserved or mildly reduced ejection fraction
por: Tang, Yi, et al.
Publicado: (2023)

Functional Recovery of a Failed Radial Artery Graft After Progression of Native Coronary Stenosis
por: Anastasiou, Ioannis, et al.
Publicado: (2020)

Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA‐HF
por: Dewan, Pooja, et al.
Publicado: (2021)

Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction
por: Coculescu, Bogdan Ioan, et al.
Publicado: (2018)

Cost‐effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China
por: Yao, Younan, et al.
Publicado: (2020)

Dapagliflozin in the treatment of patients with heart failure with reduced left ventricular ejection fraction – a practical approach
por: Nessler, Jadwiga
Publicado: (2021)

The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial
por: Nassif, Michael E., et al.
Publicado: (2021)

Combined treatment with sacubitril/valsartan plus dapagliflozin in patients affected by heart failure with reduced ejection fraction
por: Jiang, Juan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u682sopb1ajq9c0bse3lsutjiq